ICON has extensive experience in cardiovascular clinical research trials across the entire drug development spectrum
Our expertise ranges from the initial studies in Phase I through post-marketing efforts in Phase IV. ICON also provides specialist imaging expertise and an extensive range of specialised assays to support any cardiovascular indication.
Over the past 5 years ICON has worked on
Our clinical trial experience includes but is not limited to the following cardiovascular indications:
- Acute coronary syndrome (ACS)
- Atrial Fibrillation
- Cardiovascular Prevention
- Cerebrovascular Disease
- Congestive Heart Failure
- Coronary Artery Disease
- Myocardial Infarction
- Peripheral Artery Disease
- Pulmonary Artery Hypertension
Thriving in Value-Based Healthcare: A Guide for Cardiovascular Medical Device ManufacturersDownload the White Paper
Cardiovascular Therapeutic Area Group
ICON has a global team of in-house Cardiovascular experts, known as a Therapeutic Area Group (TAG), who are highly-experienced in clinical research and drug development. The group includes representatives from all critical functional areas and oversees trial operations in order to anticipate and proactively address potential roadblocks.
In addition to providing support and guidance to the study team, the other main responsibilities of the TAG teams include:
- Global project feasibility
- Protocol development, review and evaluation
- Clinical trial planning
- Therapeutic training and advice
- Project oversight
- Consulting, medical monitoring and advisory board representation
- Interpretation of the clinical data
- Completion of the clinical study report
Our global investigator database includes over 2,800 cardiovascular investigative sites across more than 55 countries. As such, we have established solid working relationships with leading cardiovascular sites in all regions of the world, enabling us to provide our sponsors with efficient recruitment strategies tailored to each individual study.
We have worked with a wealth of speciality investigators in multiple areas of cardiovascular disease.